Generating new evidence to REduce major COMplications to iMprove the safety and efficacy of Extracorporeal membrane oxygenatioN [ECMO] in severe cardiac and respiratory failure Platform Trial [RECOMMEND] (NCT06526533)

RECOMMEND is studying how to improve care for adults who need extracorporeal membrane oxygenation (ECMO), a form of life support for severe heart or lung failure. At The Alfred, the study compares two usual approaches to deciding when a red blood cell transfusion is given, to learn which approach is safer and leads to better outcomes.

Trial phase

Phase 3

Trial participation type

This trial is for clinical research of something other than a drug or device.

Principal investigator

Dr Aidan Burrell

Key inclusion data

Aged 18 years or older and receiving VA- or VV-ECMO. Enrolled, or expected to be enrolled, in the EXCEL ECMO Registry. Randomisation must occur within 12 hours of starting the current ECMO run. Not eligible if pregnant, listed for solid-organ transplant, or there is a decision to limit life-sustaining treatment. Not eligible if enrolled in RECOMMEND within 28 days, if ECMO was used earlier in the same admission, or if either transfusion approach is unsuitable.